Nitric oxide (NO) has been proposed to modulate the renal response to protein as well as basal renal hemodynamics. We investigated whether NO and angiotensin II (All) interact to control glomerular hemodynamics and absolute proximal tubular reabsorption (APR) during glycine infusion and in unstimulated conditions. In control rats, glycine increased single nephron GFR and plasma flow with no change in APR. The NO synthase blocker, NG-monomethyl L-arginine (LNMMA), abolished the vasodilatory response to glycine, possibly through activation of tubuloglomerular feedback due to a decrease in APR produced by LNMMA + glycine. Pretreatment with an AII receptor antagonist, DuP 753, normalized the response to glycine st both glomerular and tubular levels. In unstimulated conditions, LNMMA produced glomerular arteriolar vasoconstriction, decreased the glomerular ultrafiltration coefficient, and reduced single nephron GFR. These changes were associated with a striking decrease in APR. DuP 753 prevented both glomerular and tubular changes induced by LNMMA. In conclusion, NO represents a physiological antagonist of All at both the glomerulus and tubule in both the basal state and during glycine infusion; and inhibition of NO apparently enhances or uncovers the inhibitory effect of All on proximal reabsorption. (J. Clin. Invest. 1992Invest. . 89:1248Invest. -1256
Introduction
An increase in GFR and plasma flow during amino acid infusion or after a protein load has been demonstrated in both humans and experimental animals (1) (2) (3) (4) . The mechanism underlying the renal response to proteins is still ill defined; various humoral factors and a suppression of tubuloglomerular feedback (TGF)' have been proposed as possible mediators of amino acid-induced hyperfiltration (5) (6) (7) (8) (9) (10) . More recently, significant evidence has accumulated related to the possibility that endothelial-derived relaxing factor could play an impor-tant role in the renal hyperemia associated with amino acid infusion (1 1, 12) . The widespread interest raised by this physiological phenomenon is magnified and is potentially related to studies demonstrating a crucial role for chronic glomerular hyperfiltration in the progression of renal damage (13) (14) (15) (16) .
Two different groups have recently shown that endothelialderived relaxing factor or nitric oxide (NO) is involved not only in the regulation of basal renal hemodynamics but also in the renal response to amino acids, since normal rats pretreated with the NO synthase inhibitor, N0-monomethyl L-arginine (LNMMA), did not demonstrate an increase in GFR and renal plasma flow during amino acid or glycine infusion (1 1, 12) . Although these studies have demonstrated the importance of NO in the renal response to amino acids, the mechanism by which LNMMA prevented the normal response to glycine or amino acids has not been clarified.
The absence of changes in GFR and renal plasma flow observed in normal rats treated with LNMMA is similar to the findings demonstrated in our laboratory in rats with renovascular hypertension (17) , experimental diabetes (18) , and chronic glomerulonephritis (unpublished observation). In these pathophysiological states, the lack of response to glycine was associated with a significant reduction in proximal tubular reabsorption. Administration of converting enzyme inhibitors restored proximal tubular reabsorption and a normal increase in GFR after glycine, suggesting a potential role for angiotensin II (All). Our findings in pathophysiological conditions have led us to evaluate whether decreases in absolute proximal tubular reabsorption (APR) may constitute an important mechanism that might explain the lack ofresponse to glycine in normal rats treated with LNMMA. Furthermore, since previous in vitro and in vivo studies have suggested an important interaction between All and NO at the glomerular level (1 1, 19) , we have investigated the possibility of similarly important interactions in the proximal tubule.
The present study was designed to answer the following questions: (a) What is the specific role ofNO in the glomerular and tubular response to glycine infusion? (b) Do 
Experimental design
The studies were conducted in 39 male Munich-Wistar rats (200-270 g body wt) obtained from Simonsen Laboratories (Gilroy, CA). Eight groups of rats were divided into two different protocols as demonstrated in Fig. 1 . Protocol L Role ofNO and All in the normal response to glycine infusion. After euvolemic replacement, rats were submitted to basal measurements of glomerular hemodynamics and proximal tubular reabsorption. After completion of basal measurements, glycine was dissolved in isotonic NaCl-NaHCO3 at a concentration of 2.66 M (20 g%) and infused at -1.4 ml/h throughout the remainder ofthe experiment. 30 min after beginning glycine, measurements of glomerular hemodynamics and proximal tubular reabsorption were repeated (experimental measurements).
Four groups of rats were studied. Group Ia (n = 6) comprised control unmanipulated rats, which only received glycine during the experimental period. In group lb (n = 6), LNMMA (Calbiochem, Corp., La Jolla, CA), dissolved in isotonic NaCl-NaHCO3, was infused simultaneously with glycine at a rate of0.5 mg/kg per min and was continued throughout the remainder of the study. Both solutions were contained in the same syringe and started at the same time. This dose ofLNMMA does not modify GFR as demonstrated by Tolins et al. (20) . In group Ic (n = 6), the nonpeptide All receptor antagonist, 2-n-butyl-4-chloro-5-hydroxymethyl-l-[2'-( lH-tetrazole-5-biphenyl-4-yl)methyl] imidaz ole, DuP 753 (21) , was administered at the end ofthe surgical preparation as an intravenous bolus (10 mg/kg dissolved in 2.7 ml of Ringer solution). Measurements were obtained in basal conditions and during concurrent infusion ofglycine and LNMMA. In group Id, we evaluated whether the changes in glomerular and tubular function observed during LNMMA infusion in group lb were specific to inhibition of NO synthesis. Group Id comprised three rats pretreated with L-arginine, the natural precursor of NO, using a 10-fold excess concentration of L-arginine to LNMMA. In this group, after completion ofthe surgical preparation, L-arginine was dissolved in the isotonic NaCl-NaHCO3 solution containing [3H] inulin and infused at a rate of 5 mg/kg per min.
Single nephron GFR (SNGFR) and proximal tubular reabsorption were measured in basal period and during infusion of LNMMA + glycine as in group lb.
Protocol I. Glomerular and tubular interaction between NO and All in unstimulated conditions. In this study, measurements ofglomerular and tubular function were obtained after euvolemic replacement as in the previous protocol (BASAL). After completion of basal measurements, LNMMA infusion (0.5 mg/kg per min) was begun and continued throughout the experiment. 30 tance (ER), and oncotic pressure (r) from protein concentration were calculated as described in previous publications (22, 25).
To calculate proximal reabsorption, the volume ofthe samples collected from late proximal tubules was transferred to a previously calibrated, constant-bore capillary tube. The volume of tubular fluid was determined from length measurements in this capillary tube. From the total radioactivity count rate and the known volume, the tubular fluid inulin concentration (TF) can be determined, and from the plasma inulin radioactivity (P) (corrected for plasma water), the TF/P. Fractional tubular reabsorption (FR) at the late proximal tubule site can be determined from the TF/P ratio from the following relationship: FR = (1 -P/TF) x 100%. Absolute tubular fluid reabsorption in the proximal tubule (APR) can be determined from: APR = SNGFR x FR (23) .
Changes in SNPF modify the profile ofthe mean effective filtration pressure (EFP) along the glomerular capillary by affecting the rate at which protein is concentrated and the rate of rise in r along x*. The SNGFR can therefore be determined as follows: SNGFR = LpA X EFP where LpA is the glomerular ultrafiltration coefficient, which in turn is a product of the hydraulic conductivity (Lp) of the glomerular membrane and A, the effective filtering surface area ofthe glomerular capillary. LpA is computed by using an iterative procedure as previously described (26 Pretreating the rats with L-arginine (group Id) blunted the increase in blood pressure observed in group Tb (Table I) ; in arginine-treated rats no significant change in MAP was detected during LNMMA + glycine infusion (MAP was 102±3 mmHg in basal period and 110±2 mmHg during glycine + LNMMA), whereas untreated rats (group Tb) responded to the same infusion with a 23% increase in MAP. Fig. 3 shows the Protocol II Glomerular and tubular interaction between NO and AII. In this study we evaluated the effects ofinhibition ofNO synthesis on unstimulated glomerular and tubular dynamics. No difference was detected in body weight between control rats (234±6 g) and DuP 753 rats (225±9 g). The results of the glomerular hemodynamic study in untreated rats (group IIa) and DuP 753-treated rats (group IIb) are reported in Remarkable results were obtained from the examination of tubular reabsorption in these groups ofrats; results are depicted in Fig. 4 . As observed in protocol I, DuP 753 administration was associated with decreased proximal reabsorption. In DuP 753-treated rats (group Ilb), basal values of APR and FR were 11.5±1.3 nl/min and 0.34±0.02, respectively; whereas in untreated rats, APR was 15.7±1.2 nl/min and FR was 0.40±0.02 (P < 0.05). The most striking result was the impressive decrease in proximal reabsorption detected during LNMMA infusion in untreated control rats. In this group, LNMMA infusion decreased APR 47% and FR 35% (P < 0.05 vs. control period). As observed in protocol I, DuP 753 treatment before LNMMA infusion (group Ilb) prevented the reduction in APR and FR as well the glomerular vasoconstriction, suggesting an interaction between All and NO in the control of both basal and stimulated glomerular and tubular function.
As observed in DuP 753-treated rats, saralasin administration (group 1Ic) did not prevent the increase in MAP induced by LNMMA (99.8±4.7 mmHg, first period; 128.7±5.6 mmHg during LNMMA, P < 0.05). Saralasin also resulted in prevention ofthe decrease in both SNGFR and proximal reabsorption during LNMMA (Fig. 5) . In saralasin-treated rats, SNGFR was 39.7±1.9 nl/min in the first period and 40.8±2.1 nl/min during LNMMA; similarly both APR and FR did not change significantly between the two periods, APR was 17.1 ±1 and 18.6±1 nl/min, respectively, FR was 0.43±0.02 before and 0.47±0.02 after LNMMA. These data clearly demonstrate that DuP 753 prevents the LNMMA effects on both glomerular and tubular function through All antagonism rather than other AII-independent mechanisms. When L-arginine was infused concurrently with LNMMA (10-fold excess of L-arginine to LNMMA) in group IId rats, no change was detected in blood pressure, SNGFR, or tubular reabsorption. L-Arginine prevented the increase in MAP observed in untreated rats during LNMMA infusion (group IIa); in group lId, MAP was 112±4 mmHg in the basal period and 115±7 mmHg during infusion of L-arginine + LNMMA. As depicted in Fig. 6 (31) . However, the in vitro techniques used in Ishii's study precluded any conclusion of a role for NO in affecting tubular transport. Other studies have shown that proximal convoluted tubules are capable of the synthesis of L-arginine, the substrate for this reaction (32) .
The mechanism by which NO inhibition decreases proximal reabsorption has yet to be defined. The (35) . Blockade with DuP 753 ofboth the inhibitory as well as the stimulatory effects of All on proximal tubular reabsorption can explain the absence of changes in APR in the presence of both DuP and LNMMA (group 1Ib). One could postulate that under both All and NO blockade, glomerulotubular balance may be the overriding factor that determines proximal tubular reabsorption, such that increases in SNGFR are associated with increases in APR as seen in our group Ic. The experimental technique used in this study precludes any further analysis of the interaction between All and NO in the control of proximal tubular reabsorption but provides important observations for future research.
NO appears to mediate the renal hyperemia and hyperfiltration after acute amino acid infusion. Two different studies have demonstrated that LNMMA inhibits the increase in GFR and renal plasma flow observed during amino acid or glycine infusion in normal rats, however, none of these studies has provided insights regarding the mechanism underlyingthis phenomenon (1 1, 12 ). The present study confirms the importance of NO release in the response to glycine. Infusion of LNMMA (group Ib, Table I ) induced systemic vasoconstriction, an increase in blood pressure, absence of vasodilation during glycine, and a significant reduction in LpA. The changes in glomerular hemodynamics were coincident with significant decreases in both APR and FR (Fig. 2) . Although there is a debate on the role ofthe TGF on the protein-induced increase in GFR (36) (37) (38) , on the basis of our findings, we can speculate that the absence ofa response to glycine during LNMMA is most likely the result ofactivation ofTGF due to increases in distal tubular delivery. We have previously demonstrated in three different experimental models of renal injury in rats, two-kidney oneclip Goldblatt hypertension (17) , diabetes mellitus (18) , and experimental glomerulonephritis (unpublished observations), the presence of a correlation between lack of normal response to glycine, and reduction in proximal tubular reabsorption. In these conditions, as in the current study, an activation of the TGF system may be responsible for limiting the response. However, under pathophysiological conditions (experimental diabetes and Goldblatt hypertension) we have recently obtained evidence that TGF activation may not be the only factor that limits the response to glycine, since restoring tubular reabsorption to normal values is not sufficient to restore the response to glycine (reference 18; unpublished observations).
In conclusion, the present study demonstrates for the first time that NO is a physiological antagonist of AII at both the glomerular and tubular level. Such an interaction may be a critical factor in the control of the basal renal function and, moreover, in the tubular and glomerular response to glycine.
